Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers.

@article{Kutty2013CetuximabCV,
  title={Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers.},
  author={R. V. Kutty and S. Feng},
  journal={Biomaterials},
  year={2013},
  volume={34 38},
  pages={
          10160-71
        }
}
  • R. V. Kutty, S. Feng
  • Published 2013
  • Medicine, Materials Science
  • Biomaterials
  • We developed a system of Cetuximab-conjugated micelles of vitamin E TPGS for targeted delivery of docetaxel as a model anticancer drug for treatment of the triple negative breast cancer (TNBC), which shows no expression of either one of the hormone progesterone receptor (PR), estrogen receptor (ER) and epidermal growth factor receptor 2 (HER2) and is thus more difficult to be treated than the positive breast cancer. Such micelles are of desired particle size, drug loading, drug encapsulation… CONTINUE READING

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 56 REFERENCES
    Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles.
    • 76
    Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
    • 2,891
    • PDF